Capstan: bringing mRNA to in vivo CAR Ts

With $165 million in funding and technology from a group of Penn heavyweights including Carl June and Bruce Levine, Capstan launched with plans to address some of the biggest problems with cell therapies through non-viral, in vivo cell engineering platforms. 

Based on the biotech’s investor syndicate, at least several pharmas seem to believe in vivo cell therapies could be the next application to benefit from advances in mRNA science...